{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '9.1.', 'Overview', '46', '9.2.', 'Study Population Definitions', '46', '9.3.', 'Sample Size and Power Considerations', '46', '9.4.', 'Background and Demographic Characteristics', '47', '9.5.', 'Subject Disposition', '47', '9.6.', 'Efficacy Analysis', '47', '9.6.1.', 'Primary Endpoint', '47', '9.6.2.', 'Secondary and Exploratory Efficacy Endpoints', '48', '9.6.3.', 'Photography', '48', '48', '9.6.5.', 'Multiplicity Adjustment', '49', '9.7.', 'Safety Analysis', '49', '9.8.', 'Interim Analysis', '49', '9.9.', 'Other Topics', '49', '9.9.1.', 'Investigational Product Compliance (Tablets)', '49', '9.9.2.', 'Concomitant Therapy', '50', '9.9.3.', 'Steering Committee', '50', '10.', 'ADVERSE EVENTS', '51', '10.1.', 'Monitoring, Recording and Reporting of Adverse Events', '51', '10.2.', 'Evaluation of Adverse Events', '51', '10.2.1.', 'Seriousness', '51', '10.2.2.', 'Severity / Intensity', '53', '10.2.3.', 'Causality', '53', '10.2.4.', 'Duration', '54', '10.2.5.', 'Action Taken', '54', '10.2.6.', 'Outcome', '54', '10.3.', 'Abnormal Laboratory Values', '54', '10.4.', 'Pregnancy', '55', '10.4.1.', 'Females of Childbearing Potential - Collection of Pregnancy Information', '55', '10.4.2.', 'Male Subject With Partners Who Become Pregnant', '56', '10.4.3.', 'Collection of Lactation Information', '56', '10.5.', 'Reporting of Serious Adverse Events', '56', '10.5.1.', 'Safety Queries', '57', 'Confidential and Proprietary', '12', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '10.6.', 'Expedited Reporting of Adverse Events', '57', '11.', 'DISCONTINUATIONS', '59', '11.1.', 'Treatment Discontinuation', '59', '11.2.', 'Study Discontinuation', '59', '12.', 'EMERGENCY PROCEDURES', '61', '12.1.', 'Emergency Contact', '61', '12.2.', 'Emergency Identification of Investigational Products', '61', '13.', 'REGULATORY CONSIDERATIONS', '62', '13.1.', 'Good Clinical Practice', '62', '13.2.', 'Investigator Responsibilities', '62', '13.3.', 'Subject Information and Informed Consent', '63', '13.4.', 'Confidentiality', '63', '13.5.', 'Protocol Amendments', '63', '13.6.', 'Institutional Review Board/Independent Ethics Committee Review and', 'Approval', '64', '13.7.', 'Ongoing Information for Institutional Review Board/Ethics Committee', '64', '13.8.', 'Termination of the Study', '65', '14.', 'DATA HANDLING AND RECORDKEEPING', '66', '14.1.', 'Data/Documents', '66', '14.2.', 'Data Management', '66', '14.3.', 'Record Retention', '66', '15.', 'QUALITY CONTROL AND QUALITY ASSURANCE', '68', '15.1.', 'Study Monitoring and Source Data Verification', '68', '15.2.', 'Audits and Inspections', '68', '15.3.', 'Product Complaint', '68', '15.3.1.', 'How to Report a Product Complaint to Amgen', '69', '16.', 'PUBLICATIONS', '70', '17.', 'REFERENCES', '71', '18.', 'APPENDICES', '72', 'Appendix A: Table of Abbreviations', '72', 'Appendix B: The Dermatology Life Quality Index (DLQI)', '75', 'Appendix C: Static Physicians Global Assessment (sPGA) Of Visible Locations', '77', 'Appendix D: Scalp Physician Global Assessment (ScPGA)', '78', 'Confidential and Proprietary', '13', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Appendix E: Nail Psoriasis Severity Index (NAPSI)', '79', 'Appendix F: Modified Static Physicians Global Assessment of Genitalia (Modified', 'sPGA-G)', '80', 'Appendix G: Palmoplantar Psoriasis Physicians Global Assessment (PPPGA)', '81', 'Appendix H: Itch Numeric Rating Scale (NRS)', '82', 'Appendix I: Skin Discomfort/Pain Visual Analog Scale (VAS)', '83', 'Appendix J: Psoriasis Area Severity Index (PASI)', '84', 'Appendix K: Patient Needs Questionnaire (PNQ)', '85', 'Appendix L: Patient Benefit Questionnaire (PBQ)', '86', 'Appendix', 'M:', 'European Quality of Life 5-Dimension Questionnaire (EQ-5D)', '87', 'Appendix N: Work Productivity and Activity Impairment Questionnaire: Psoriasis', '(WPAI: PSO)', '90', 'Appendix O: Waist Circumference Measurement & Body Mass Index', '91', 'Appendix P: Treatment Schema for Dose Titration at Baseline', '92', 'Appendix Q: Treatment Schema for Dose Titration at Week 16', '93', 'Appendix R: Titration Blister Card', '94', 'Appendix S: Sample Serious Adverse Event Form', '95', 'Appendix T: Pregnancy Notification Form', '98', 'Appendix U: Lactation Notification Form', '99', 'Confidential and Proprietary', '14', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'LIST OF TABLES', 'Table 1:', 'Study Objectives', '20', 'Table 2:', 'Study Endpoints', '20', 'Table 3: Table of Events', '29', 'Table 4:', 'Abbreviations and Specialist Terms', '72', 'Confidential and Proprietary', '15', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}